ArticleCNS neuroscience & therapeutics2026
The Anti-Inflammatory Effect of Yangyin Tongnao Granule on Cerebral Ischemia-Reperfusion Injury in Rats.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Assessment of Stroke Severity: Development of a Visual Infarct and Comprehensive Scoring System in Ischemic Rats With Middle Cerebral Artery Occlusion.The European journal of neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundYangyin Tongnao (YYTN) granule is a classic traditional Chinese medicine (TCM) preparation known for its therapeutic efficacy in promoting blood circulation, resolving stasis, nourishing yin, and reinforcing qi. Its neuroprotective effects have been validated through both clinical and preclinical studies.
methodsA middle cerebral artery occlusion (MCAO) rat model was established, and rats were randomly assigned to five groups: Sham, MCAO, YYTN, Ag490 (JAK2 inhibitor), and Ag490 + YYTN. YYTN was administered intragastrically at 1.73 g/kg/day, while Ag490 was administered via lateral ventricle injection at a volume of 10 μL per rat. Neurological function was assessed using Garcia scores, and infarct volume was determined by TTC staining. Neuronal integrity and damage were evaluated through HE and Nissl staining. Plasma levels of IL-18 and TNF-α were measured via ELISA, and the mRNA expression of IL-6 and IL-1β was quantified by RT-qPCR. Inflammatory markers, including p-JAK2, p-STAT3, NLRP3, ASC, cl-Caspase-1, and cl-IL-1β, were assessed by Western blotting. The distribution of p-JAK2 and p-STAT3 in brain sections was visualized via immunofluorescence staining.
resultsTreatment with YYTN significantly improved neurological function, reduced infarct volumes, and mitigated histopathological damage in the brain. Furthermore, YYTN significantly decreased plasma levels of IL-18 and TNF-α. In brain tissue, YYTN downregulated the mRNA expression of IL-6 and IL-1β and reduced key inflammatory proteins, including p-JAK2, p-STAT3, NLRP3, ASC, cl-Caspase-1, and cl-IL-1β.
conclusionThese findings suggest that YYTN mitigates cerebral ischemia-reperfusion injury (CIRI)-induced neuroinflammation by inhibiting the JAK2/STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.